View source for Reference:EU Regulation (EU) 2017/745 - Medical Device Regulation 20-Mar-2023 Article 77 Paragraph 5

{{#set:
|HasDocument=Document:EU Regulation (EU) 2017/745 - Medical Device Regulation 20-Mar-2023
|RefScope=MD
|RefDocPart=Article 77 
Paragraph 5
|RefLanguage=EN
|RefTagsEN=
|RefTagsOriginal=
|RefTagsFR=
}}

{{:Document:EU Regulation (EU) 2017/745 - Medical Device Regulation 20-Mar-2023}}

{| class="wikitable gplx-infobox"
|-
! colspan="2" class="gplx-infobox-header" | Reference Details
|-
! Scope
| MD
|-
! Document part
| Article 77 
Paragraph 5
|-
! Language
| EN
|-
! Original entry by
| Florian Adragna
|-
! Contributors
| 
|-
! Tags (EN)
| 
|-
! Tags (original language)
| 
|-
! Tags (FR)
| 
|-
! Comment
| Irrespective of outcome: sponsor reporting obligation within one year
|}

== Content ==
5.   Irrespective of the outcome of the clinical investigation, within one year of the end of the clinical investigation or within three months of the early termination or temporary halt, the sponsor shall submit to the Member States in which a clinical investigation was conducted a clinical investigation report as referred to in Section 2.8 of Chapter I and Section 7 of Chapter III of Annex XV.
The clinical investigation report shall be accompanied by a summary presented in terms that are easily understandable to the intended user. Both the report and summary shall be submitted by the sponsor by means of the electronic system referred to in Article 73.

Where, for scientific reasons, it is not possible to submit the clinical investigation report within one year of the end of the investigation, it shall be submitted as soon as it is available. In such case, the clinical investigation plan referred to in Section 3 of Chapter II of Annex XV shall specify when the results of the clinical investigation are going to be available, together with a justification.